Sep. 3 at 3:20 PM
$MRKR
‘Biggest development in decades’
The US Food and Drug Administration has approved a drug called daraxonrasib (Rasonque) for people with metastatic pancreatic cancer who have already tried chemotherapy. “It’s the biggest development we’ve had in pancreas cancer in decades,” says medical oncologist Andrew Ko. The approval is based on clinical trial results released earlier this year, which found that people given daraxonrasib survived for about one year on average whereas those given chemotherapy lived for about six months. More than 2,000 people have accessed the drug so far, which costs up to US
$39,800 per month before insurance and is taken as two pills a day.
By Nature.
